Treatment of immune-mediated extraintestinal manifestations of inflammatory bowel disease with infliximab

被引：19
作者：
Barrie, Arthur
Plevy, Scott
机构：
[1] Univ N Carolina, Div Gastroenterol & Hepatol, Sch Med, Chapel Hill, NC 27599 USA
[2] Univ Pittsburgh, Sch Med, Div Gastroenterol Hepatol & Nutr, Pittsburgh, PA 15261 USA
来源：
GASTROENTEROLOGY CLINICS OF NORTH AMERICA | 2006年 / 35卷 / 04期
关键词：
D O I：
10.1016/j.gtc.2006.09.001
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
Extraintestinal manifestations (EIM) associated with the chronic inflammatory bowel diseases (IBD) ulcerative colitis and Crohn's disease (CD) have a negative impact on morbidity and even mortality in a significant percentage of patients who have IBD. The chimeric (mouse/human) anti-tumor necrosis factor IgG1 monoclonal antibody infliximab is highly effective for the induction and maintenance of remission in moderate-to-severe CD and ulcerative colitis resistant to conventional therapies. Additionally, infliximab has emerged as an effective treatment for immune-mediated EIM often refractory to other interventions. This article reviews experiences with infliximab to treat immune-mediated EIM of IBD.
引用
收藏
页码：883 / +
页数：12
相关论文
共 76 条
[1]   Macrophages expressing the scavenger receptor CD163: a link between immune alterations of the gut and synovial inflammation in spondyloarthropathy [J].
Baeten, D ;
Demetter, P ;
Cuvelier, CA ;
Kruithof, E ;
Van Damme, N ;
De Vos, M ;
Veys, EM ;
De Keyser, F .
JOURNAL OF PATHOLOGY, 2002, 196 (03) :343-350
[2]   Successful treatment with infliximab and methotrexate of pyostomatitis vegetans associated with Crohn's disease [J].
Bens, G ;
Laharie, D ;
Beylot-Barry, M ;
Vergier, B ;
Noblesse, I ;
Beylot, C ;
Amouretti, M .
BRITISH JOURNAL OF DERMATOLOGY, 2003, 149 (01) :181-184
[3]  
Bernstein CN, 2001, AM J GASTROENTEROL, V96, P1116
[4]   The clustering of other chronic inflammatory diseases in inflammatory bowel disease: A population-based study [J].
Bernstein, CN ;
Wajda, A ;
Blanchard, JF .
GASTROENTEROLOGY, 2005, 129 (03) :827-836
[5]   The immunological and genetic basis of inflammatory bowel disease [J].
Bouma, G ;
Strober, W .
NATURE REVIEWS IMMUNOLOGY, 2003, 3 (07) :521-533
[6]  
Brandt J, 2000, ARTHRITIS RHEUM-US, V43, P1346, DOI 10.1002/1529-0131(200006)43:6<1346::AID-ANR18>3.0.CO
[7]  
2-E
[8]   Two year maintenance of efficacy and safety of infliximab in the treatment of ankylosing spondylitis [J].
Braun, J ;
Brandt, J ;
Listing, J ;
Zink, A ;
Alten, R ;
Burmester, G ;
Gromnica-Ihle, E ;
Kellner, H ;
Schneider, M ;
Sörensen, H ;
Zeidler, H ;
Sieper, J .
ANNALS OF THE RHEUMATIC DISEASES, 2005, 64 (02) :229-234
[9]   Decreased incidence of anterior uveitis in patients with ankylosing spondylitis treated with the anti-tumor necrosis factor agents infliximab and etanercept [J].
Braun, J ;
Baraliakos, X ;
Listing, J ;
Sieper, J .
ARTHRITIS AND RHEUMATISM, 2005, 52 (08) :2447-2451
[10]   Treatment of active ankylosing spondylitis with infliximab:: a randomised controlled multicentre trial [J].
Braun, J ;
Brandt, J ;
Listing, J ;
Zink, A ;
Alten, R ;
Golder, W ;
Gromica-Ihle, E ;
Kellner, H ;
Krause, A ;
Schneider, M ;
Sörensen, H ;
Zeidler, H ;
Thriene, W ;
Sieper, J .
LANCET, 2002, 359 (9313) :1187-1193
12345678